• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Mirikizumab induces clinical remission in patients with ulcerative colitis

byBryant LimandKiera Liblik
July 14, 2023
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, patients with ulcerative colitis taking mirikizumab had higher rates of clinical remission compared to those taking a placebo.

2. Opportunistic infections occurred more frequently in the mirikizumab group. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recent clinical trials and approval of monoclonal antibody treatments for ulcerative colitis suggest interleukin-23 as a promising therapeutic target. Mirikizumab is a humanized monoclonal antibody that binds a subunit of interleukin-23. In this study, two phase three trials evaluating the efficacy of mirikizumab induction and maintenance for adult patients with moderate to severe treatment-resistant ulcerative colitis were reported. In the induction trial, patients received intravenous mirikizumab or placebo every four weeks for 12 weeks. In the maintenance trial, patients with clinical response to mirikizumab during the induction trial underwent randomization again to receive blinded subcutaneous mirikizumab or placebo every four weeks over an additional 40 weeks. The primary outcome was clinical remission at week 12 for the induction trial and week 40 for the maintenance trial. A significantly higher percentage of patients in the mirikizumab group achieved the primary outcome for both the induction and maintenance trials. Secondary outcomes in the induction trial were endoscopic remission, clinical response in patients with previous treatment failure, histologic-endoscopic mucosal improvement, and bowel-movement urgency. Secondary outcomes were superior in the mirikizumab group. For safety, the incidence of opportunistic infection and immediate hypersensitivity reactions was more frequent in the mirikizumab group. As a limitation, less than 1% of patients in each trial were Black, which may lead to lower generalizability of the study. Overall, mirikizumab improved remission in ulcerative colitis patients.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: In this study, two phase three trials evaluating the efficacy of mirikizumab induction and maintenance for adult patients with moderate to severe treatment-resistant ulcerative colitis (n=1,162) were reported. In the induction trial, patients were randomly assigned to receive mirikizumab 300mg (n=868) or a placebo (n=294) every four weeks for 12 weeks. In the maintenance trial, 544 patients with clinical responses to mirikizumab were randomly assigned to receive mirikizumab 200mg (n=365) or placebo (n=179) every four weeks for 40 weeks. In the induction trial, the primary outcome of clinical remission at week 12 was significantly higher in the mirikizumab group than in the placebo group (24.2% and 13.3%, respectively; difference, 11.1 percentage points; 99.875% Confidence Interval [CI], 3.2 to 19.1; p<0.001). The primary outcome in the maintenance trial of clinical remission at week 40 was significantly higher in the mirikizumab group than in the placebo group (49.9% and 25.1%, respectively; difference, 23.2 percentage points; 95% CI, 15.2 to 31.2; p<0.001). Secondary outcomes in the induction trial of endoscopic remission, clinical response in patients with previous treatment failure with a biologic agent or tofacitinib, histologic-endoscopic mucosal improvement, and bowel-movement urgency were significantly superior in the mirikizumab group (p<0.001 for all comparisons). Secondary outcomes in the maintenance trial of glucocorticoid-free clinical remission, endoscopic remission, histologic remission, and bowel remission were significantly greater in the mirikizumab group (p<0.001 for all comparisons). For safety, the incidence of opportunistic infection and immediate hypersensitivity reactions were more frequent in the mirikizumab group. In summary, mirikizumab therapy was efficacious in both the induction and maintenance of remission in patients with ulcerative colitis.

RELATED REPORTS

Multidomain rehabilitation after myocardial infarction improves outcomes in older adults

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

Limiting antihypertensive use does not reduce mortality in nursing home residents with frailty

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseaseGastroenterologyinfectious diseaseinterleukin-23MirikizumabOpportunistic infectionsUlcerative Colitis
Previous Post

Digital cognitive behavioral therapy improves insomnia symptoms in stroke survivors

Next Post

#VisualAbstract: Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Multidomain rehabilitation after myocardial infarction improves outcomes in older adults

October 15, 2025
Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)
Cardiology

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

October 14, 2025
Cardiology

Limiting antihypertensive use does not reduce mortality in nursing home residents with frailty

October 14, 2025
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Digitoxin improves outcomes in heart failure with reduced ejection fraction

October 14, 2025
Next Post
#VisualAbstract: Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke

#VisualAbstract: Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke

Incidence and severity of dengue in pediatric patients higher in Southeast Asia versus Latin America

Complicated cases of severe dengue rarely occur in infected travelers

Increased risk of non-melanoma skin cancer with subsequent keratinocytes carcinoma

Patient Perspective of Opioid Pain-Control Use After Mohs Micrographic Surgery

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind October 20, 2025
  • Rate of incident dementia and care needs among older adults with new traumatic brain injury: a population-based cohort study
  • Self-Help App for Depression in People With Intellectual Disabilities: A Randomized Clinical Trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.